GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Screening (Form 1)

General Information
Description

General Information

Center number
Description

Center number

Data type

text

Patient Number
Description

Patient Number

Data type

integer

Patient Initials
Description

Patient Initials

Data type

text

Visit Date
Description

Visit Date

Data type

date

RLS Screen History
Description

RLS Screen History

1. How old was the patient at the onset of RLS?
Description

1. How old was the patient at the onset of RLS?

Data type

integer

Measurement units
  • Years
Years
2. Did the patient start any new medication near the time of their onset of RLS symptoms that may have caused RLS?
Description

2. Did the patient start any new medication near the time of their onset of RLS symptoms that may have caused RLS?

Data type

text

If yes, please specify medication
Description

Specification of medication

Data type

text

3. If female, did RLS symptoms develop during pregnancy?
Description

3. If female, did RLS symptoms develop during pregnancy?

Data type

text

4. Has the patient ever had PLMS (Periodic Leg Movements of Sleep)?
Description

4. Has the patient ever had PLMS (Periodic Leg Movements of Sleep)?

Data type

text

If yes, how old was the patient at the onset of PLMS?
Description

If yes, how old was the patient at the onset of PLMS?

Data type

integer

Measurement units
  • Years
Years
5. Does the patient drink alcohol?
Description

5. Does the patient drink alcohol?

Data type

text

How many units per week?
Description

One unit is equivalent to: UK - 1 measure spirits, 1/2 pt beer, 1 small glass of wine US - 1.5oz hard liquor, 1 beer, 4oz wine

Data type

integer

6. Does the patient drink caffeine (coffee, tea, cafeeinated drinks)?
Description

6. Does the patient drink caffeine (coffee, tea, cafeeinated drinks)?

Data type

text

If yes, please specify amount
Description

Amount of caffeine

Data type

integer

Measurement units
  • Cups/day
Cups/day
7. Does the patient have any sleep disorder as defined by DSM IV?
Description

7. Does the patient have any sleep disorder as defined by DSM IV?

Data type

text

8. Has any first degree relative (mother/father, brother/sister, son/daughter) of the patient ever been diagnosed with or had symptoms of RLS?
Description

8. Has any first degree relative (mother/father, brother/sister, son/daughter) of the patient ever been diagnosed with or had symptoms of RLS?

Data type

text

9. Has any first degree relative (mother/father, brother/sister, son/daughter) of the patient ever been diagnosed with or had symptoms of PLMS?
Description

9. Has any first degree relative (mother/father, brother/sister, son/daughter) of the patient ever been diagnosed with or had symptoms of PLMS?

Data type

text

10. Are the patient´s current symptoms mainly present...
Description

10. Are the patient´s current symptoms mainly present...

Data type

text

RLS Diagnostic Criteria
Description

RLS Diagnostic Criteria

1)...a desire to move the limbs usually associated with parethesias or dysesthesias
Description

1)...a desire to move the limbs usually associated with parethesias or dysesthesias

Data type

boolean

2)...motor restlessness (during wakefulness does the patient move the limbs in attempt to relieve the discomfort)
Description

2)...motor restlessness (during wakefulness does the patient move the limbs in attempt to relieve the discomfort)

Data type

boolean

3) ...symptoms worse or exclusively present at rest with at least partial or temporal relief by activity
Description

3) ...symptoms worse or exclusively present at rest with at least partial or temporal relief by activity

Data type

boolean

4) ...symptoms worse in the evening or night
Description

4) ...symptoms worse in the evening or night

Data type

boolean

Demography
Description

Demography

Date of birth
Description

Date of birth

Data type

date

Gender
Description

Gender

Data type

text

Race
Description

Race

Data type

text

If other race please specify
Description

Specification of race

Data type

text

Vital signs
Description

Vital signs

Height
Description

Height

Data type

float

Measurement units
  • cm/in
cm/in
Weight
Description

Weight

Data type

float

Pulse (after 5 minutes sitting)
Description

Pulse

Data type

integer

Measurement units
  • beats/min
beats/min
Orthostatic Vital Signs
Description

Orthostatic Vital Signs

Blood pressure after 10 minutes semi-supine (systolic)
Description

Blood pressure after 10 minutes semi-supine (systolic)

Data type

integer

Blood pressure after 10 minutes semi-supine (diastolic)
Description

Blood pressure after 10 minutes semi-supine (diastolic)

Data type

integer

After 10 minutes semi-supine Pulse
Description

After 10 minutes semi-supine Pulse

Data type

integer

Measurement units
  • beats/min
beats/min
Blood pressure after erect for 1 minute (systolic)
Description

Blood pressure after erect for 1 minute (systolic)

Data type

integer

Measurement units
  • mmHg
mmHg
Blood pressure after erect for 1 minute (diastolic)
Description

Blood pressure after erect for 1 minute (diastolic)

Data type

integer

Pulse after erect for 1 minute
Description

Pulse after erect for 1 minute

Data type

integer

Measurement units
  • beats/min
beats/min
Electrocardiogramm (12 Lead)
Description

Electrocardiogramm (12 Lead)

Date of ECG
Description

Date of ECG

Data type

date

Were any clinically significant abnormalities detected?
Description

Were any clinically significant abnormalities detected?

Data type

text

Physical Examination
Description

Physical Examination

Please perform a full physical examination and record any clinically significant abnormality on the Significant Medical/Surgical History and Physical Examination Page. Physical Examination compleated?
Description

Physical Examination

Data type

boolean

Laboratory Evaluation
Description

Laboratory Evaluation

Date of blood sample
Description

Please take a blood and urine sample for routine analysis.

Data type

date

Were any clinically significant abnormalities detected?
Description

Were any clinically significant abnormalities detected?

Data type

text

Pregnancy Dipstick
Description

Pregnancy Dipstick

Is the patient a female of childbearing potential?
Description

Is the patient a female of childbearing potential?

Data type

text

Results from pregnancy dipstick
Description

Results from pregnancy dipstick

Data type

text

Significant medical/surgical history and physical examination
Description

Significant medical/surgical history and physical examination

Is the patient suffering from or has he/she ever suffered from any significant medical or surgical condition other than RLS or PLMS?
Description

Is the patient suffering from or has he/she ever suffered from any significant medical or surgical condition other than RLS or PLMS?

Data type

text

List of diagnosis other than RLS or PLMS
Description

List of diagnosis other than RLS or PLMS

Diagnosis
Description

Diagnosis

Data type

text

Year of first diagnosis (if known)
Description

Year of first diagnosis (if known)

Data type

integer

Measurement units
  • year
year
Past or ongoing?
Description

Past or ongoing?

Data type

text

Prior and Concomitant Medication
Description

Prior and Concomitant Medication

Has the patient taken any medication (excluding any pharmacotherapy medication for treatment of RLS or PLMS) in the 3 month prior to study entry?
Description

Has the patient taken any medication (excluding any pharmacotherapy medication for treatment of RLS or PLMS) in the 3 month prior to study entry?

Data type

text

Details prior and concomitant medication
Description

Details prior and concomitant medication

Drug Name (Trade Name Preferred)
Description

Drug Name

Data type

text

Total Daily Dose
Description

Total Daily Dose

Data type

text

Measurement units
  • mg
mg
Medical Illness/Diagnosis
Description

Medical Illness/Diagnosis

Data type

text

Start Date (be as precise as possible)
Description

Start Date

Data type

date

End Date (answer next question if Continuing)
Description

End Date

Data type

boolean

Medication continuing?
Description

Medication continuing?

Data type

boolean

RLS Pharmacotherapy history
Description

RLS Pharmacotherapy history

Has the patient taken any pharmacotherapy medication for treatment of RLS?
Description

Has the patient taken any pharmacotherapy medication for treatment of RLS?

Data type

text

Details RLS pharmacotherapy history
Description

Details RLS pharmacotherapy history

Drug Name (Trade Name Preferred)
Description

Drug Name

Data type

text

Start Date (be as precise as possible)
Description

Start Date

Data type

date

End Date (or if continuing answer next question)
Description

End Date

Data type

date

Medication continuing?
Description

Medication continuing?

Data type

boolean

Did the patient respond to the treatment?
Description

Did the patient respond to the treatment?

Data type

text

Did the patient tolerate the treatment?
Description

Did the patient tolerate the treatment?

Data type

text

Screening Inclusion Criteria
Description

Screening Inclusion Criteria

1. Male or female subjects diagnosed with RLS using IRLSSG diagnostic criteria with a recent history of a minimum of 15 nights of RLS symptoms per month. Note: For a subject already receiving medication for RLS, the investigator should use their clinical judgement to decide whether that subject would suffer from a minimum of 15 nights with RLS symptoms if they were not taking any medication.
Description

IRLSSG diagnostic criteria

Data type

boolean

2. Subjects must have reported clinically significant complaints of either sleep disruption or daytime consequences associated with the sleep disturbance.
Description

Clinically significant complaints

Data type

boolean

3. Subjects >18 years and <80 years of age.
Description

Inclusion age

Data type

boolean

4. Women of child-bearing potential who are practicing a clinically accepted method of contraception such as oral contraception, surgical sterilization, IUD, diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception (i.e., Norplant). Please refer to document: CD-5.5, Informed Consent (Phase I-IV), section entitled ‘Recommendations For Use of Women Of Childbearing Potential in Clinical Research Studies for SmithKline Beecham’.
Description

Contraception

Data type

boolean

5. The subject must have given written informed consent prior to any specific study procedure.
Description

written informed consent

Data type

boolean

Usage Information seen
Description

If any of the above questions have been answered ’No’ exclude the patient from the study and complete the Patient Continuation/Withdrawal page behind the Baseline Visit Section.

Data type

boolean

Screening Exclusion Criteria
Description

Screening Exclusion Criteria

1. Subjects suffering from RLS symptoms which require treatment during the daytime (daytime defined as 10:00 until 18:00)
Description

RLS symptoms

Data type

boolean

2. Subjects who suffer from a dissomnia or parasomnia other than RLS (e.g. narcolepsy, sleep terror disorder, sleepwalking disorder, apnea/hypopnea index >5 per hour during total sleep time and a total oxygen saturation of <80%).
Description

Dissomnia or Parasomnia

Data type

text

3. Subjects suffering from movement disorders (e.g. Parkinson´s Disease, dyskinesias, and dystonias).
Description

Movement disorders

Data type

boolean

4. Subjects who have medical conditions with symptoms which could affect assessments of efficacy (e.g. diabetes, peripheral neuropathy, rheumatoid arthritis, fibromyalgia syndrome, etc.).
Description

Symptoms which could affect assessments of efficacy

Data type

boolean

5. Subjects who have had withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) and/or any drug known to substantially inhibit CYP1A2 (e.g., ciprofloxacin, fluvoxamine, cimetidine, HRT) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrollment.
Description

change in dose of hormone replacement

Data type

boolean

6. Subjects who have exhibited intolerance to ropinirole or any other dopamine agonist.
Description

intolerance to dopamine agonist

Data type

boolean

7. Subjects who meet DSM-IV criteria for substance abuse (alcohol or drugs) or substance dependence within six month prior to screening.
Description

substance abuse

Data type

boolean

8. Woman who have a positive pregnancy test or who are lactating.
Description

Pergnancy/lactating

Data type

boolean

9. Subjects who have clinically significant or unstable medical conditions which in the opinion of the investigator would render the subject unsuitable for the study (e.g. severe cardiovascular disease, symptomatic orthostatic hypotension, hepatic or renal failure, etc.).
Description

Subject unsuitable for study

Data type

text

10. Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule or other study procedures.
Description

non-compliance with the visit schedule or other study procedures

Data type

boolean

11. Participation in any clinical drug or device trial in the three month prior to the screening visit.
Description

participation in any clinical drug or device trial

Data type

boolean

Usage Information
Description

If any of the above questions have been answered "yes" exclude the patient from the study and complete the Patient Continuation/Withdrawal page behind the Baseline Visit Section.

Data type

boolean

Repeat electrocardiogram (12 Lead)
Description

Repeat electrocardiogram (12 Lead)

Date of ECG.
Description

Please perform a 12-lead ECG if any abnormality was present at screening.

Data type

date

Were any clinically significant abnormalities detected?
Description

Were any clinically significant abnormalities detected?

Data type

text

If any abnormality was present at screening please perform a physical examination. If there are any significant abnormal findings record details in the Baseline Signs and Symptoms and/or SAE section at the back of this book and exclude the patient from the study.
Description

Repeat physical examination

Data type

text

Date of sample
Description

Please take a blood and/or urine sample if any abnormality was detected at screening. Repeat laboratory evaluation

Data type

date

Were any clinically significant abnormalities detected?
Description

Were any clinically significant abnormalities detected?

Data type

text

Please complete the patient activity postcard for Screening Repeat Tests located in the poastcard section of this CRF. Detach the postcard and mail promptly. Postage has been prepaid.
Description

Patient activity postcard

Data type

text

Similar models

GSK Ropinirole in Subjects with Restless Legs Syndrome 101468/191 Screening (Form 1)

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
General Information
Center number
Item
Center number
text
Patient Number
Item
Patient Number
integer
Patient Initials
Item
Patient Initials
text
Visit Date
Item
Visit Date
date
Item Group
RLS Screen History
1. How old was the patient at the onset of RLS?
Item
1. How old was the patient at the onset of RLS?
integer
Item
2. Did the patient start any new medication near the time of their onset of RLS symptoms that may have caused RLS?
text
Code List
2. Did the patient start any new medication near the time of their onset of RLS symptoms that may have caused RLS?
CL Item
No (1)
CL Item
Yes (please specify below) (2)
Specification of medication
Item
If yes, please specify medication
text
Item
3. If female, did RLS symptoms develop during pregnancy?
text
Code List
3. If female, did RLS symptoms develop during pregnancy?
CL Item
Yes (1)
CL Item
No (2)
CL Item
Not applicable (3)
Item
4. Has the patient ever had PLMS (Periodic Leg Movements of Sleep)?
text
Code List
4. Has the patient ever had PLMS (Periodic Leg Movements of Sleep)?
CL Item
No (1)
CL Item
Yes (please answer the following question) (2)
If yes, how old was the patient at the onset of PLMS?
Item
If yes, how old was the patient at the onset of PLMS?
integer
Item
5. Does the patient drink alcohol?
text
Code List
5. Does the patient drink alcohol?
CL Item
No (1)
CL Item
Yes (please answer the following question) (2)
How many units per week?
Item
How many units per week?
integer
Item
6. Does the patient drink caffeine (coffee, tea, cafeeinated drinks)?
text
Code List
6. Does the patient drink caffeine (coffee, tea, cafeeinated drinks)?
CL Item
No (1)
CL Item
Yes (please specify below) (2)
Amount of caffeine
Item
If yes, please specify amount
integer
Item
7. Does the patient have any sleep disorder as defined by DSM IV?
text
Code List
7. Does the patient have any sleep disorder as defined by DSM IV?
CL Item
No (1)
CL Item
Yes -> If "Yes" please record on the Significant Medical/Surgical History and Physical Examination page. (2)
Item
8. Has any first degree relative (mother/father, brother/sister, son/daughter) of the patient ever been diagnosed with or had symptoms of RLS?
text
Code List
8. Has any first degree relative (mother/father, brother/sister, son/daughter) of the patient ever been diagnosed with or had symptoms of RLS?
CL Item
No (1)
CL Item
Yes (2)
CL Item
Unknown (3)
Item
9. Has any first degree relative (mother/father, brother/sister, son/daughter) of the patient ever been diagnosed with or had symptoms of PLMS?
text
Code List
9. Has any first degree relative (mother/father, brother/sister, son/daughter) of the patient ever been diagnosed with or had symptoms of PLMS?
CL Item
No (1)
CL Item
Yes (2)
CL Item
Unknown (3)
Item
10. Are the patient´s current symptoms mainly present...
text
Code List
10. Are the patient´s current symptoms mainly present...
CL Item
At nightime only (1)
CL Item
In evening and nighttime (2)
CL Item
Daytime, evening and nighttime (3)
Item Group
RLS Diagnostic Criteria
1)...a desire to move the limbs usually associated with parethesias or dysesthesias
Item
1)...a desire to move the limbs usually associated with parethesias or dysesthesias
boolean
2)...motor restlessness (during wakefulness does the patient move the limbs in attempt to relieve the discomfort)
Item
2)...motor restlessness (during wakefulness does the patient move the limbs in attempt to relieve the discomfort)
boolean
3) ...symptoms worse or exclusively present at rest with at least partial or temporal relief by activity
Item
3) ...symptoms worse or exclusively present at rest with at least partial or temporal relief by activity
boolean
4) ...symptoms worse in the evening or night
Item
4) ...symptoms worse in the evening or night
boolean
Item Group
Demography
Date of birth
Item
Date of birth
date
Item
Gender
text
Code List
Gender
CL Item
Male (1)
CL Item
Female (2)
Item
Race
text
Code List
Race
CL Item
White (1)
CL Item
Black (2)
CL Item
Oriental (3)
CL Item
Other (please specify) (4)
Specification of race
Item
If other race please specify
text
Item Group
Vital signs
Height
Item
Height
float
Weight
Item
Weight
float
Pulse
Item
Pulse (after 5 minutes sitting)
integer
Item Group
Orthostatic Vital Signs
Blood pressure after 10 minutes semi-supine (systolic)
Item
Blood pressure after 10 minutes semi-supine (systolic)
integer
Blood pressure after 10 minutes semi-supine (diastolic)
Item
Blood pressure after 10 minutes semi-supine (diastolic)
integer
After 10 minutes semi-supine Pulse
Item
After 10 minutes semi-supine Pulse
integer
Blood pressure after erect for 1 minute (systolic)
Item
Blood pressure after erect for 1 minute (systolic)
integer
Blood pressure after erect for 1 minute (diastolic)
Item
Blood pressure after erect for 1 minute (diastolic)
integer
Pulse after erect for 1 minute
Item
Pulse after erect for 1 minute
integer
Item Group
Electrocardiogramm (12 Lead)
Date of ECG
Item
Date of ECG
date
Item
Were any clinically significant abnormalities detected?
text
Code List
Were any clinically significant abnormalities detected?
CL Item
No (1)
CL Item
Yes -> If "yes", please record details on the Significant Medical/Surgical History and Physical Examination or Baseline Signs and Symptoms/SAE pages and repeat prior to baseline. (2)
Item Group
Physical Examination
Physical Examination
Item
Please perform a full physical examination and record any clinically significant abnormality on the Significant Medical/Surgical History and Physical Examination Page. Physical Examination compleated?
boolean
Item Group
Laboratory Evaluation
Date of blood sample
Item
Date of blood sample
date
Item
Were any clinically significant abnormalities detected?
text
Code List
Were any clinically significant abnormalities detected?
CL Item
No (1)
CL Item
Yes -> If "Yes", please record details on the Significant Medical/Surgical History and Physical Examination or Baseline Signs and Symptoms/SAE pages and repeat prior to baseline. (2)
Item Group
Pregnancy Dipstick
Item
Is the patient a female of childbearing potential?
text
Code List
Is the patient a female of childbearing potential?
CL Item
No (1)
CL Item
Yes -> If "yes", please perform a pregnancy dipstick test and record result below. (2)
Item
Results from pregnancy dipstick
text
Code List
Results from pregnancy dipstick
CL Item
Negative (1)
CL Item
Positive -> If "positive", please record details on the Significant Medical/Surgical History and Physical Examination and exclude the patient. (2)
Item Group
Significant medical/surgical history and physical examination
Item
Is the patient suffering from or has he/she ever suffered from any significant medical or surgical condition other than RLS or PLMS?
text
Code List
Is the patient suffering from or has he/she ever suffered from any significant medical or surgical condition other than RLS or PLMS?
CL Item
No (1)
CL Item
Yes -> If "Yes", please list below one diagnosis per line (2)
Item Group
List of diagnosis other than RLS or PLMS
Diagnosis
Item
Diagnosis
text
Year of first diagnosis (if known)
Item
Year of first diagnosis (if known)
integer
Item
Past or ongoing?
text
Code List
Past or ongoing?
CL Item
Past (1)
CL Item
Ongoing (2)
Item Group
Prior and Concomitant Medication
Item
Has the patient taken any medication (excluding any pharmacotherapy medication for treatment of RLS or PLMS) in the 3 month prior to study entry?
text
Code List
Has the patient taken any medication (excluding any pharmacotherapy medication for treatment of RLS or PLMS) in the 3 month prior to study entry?
CL Item
No (1)
CL Item
Yes -> If "Yes", please record details below. (2)
Item Group
Details prior and concomitant medication
Drug Name
Item
Drug Name (Trade Name Preferred)
text
Total Daily Dose
Item
Total Daily Dose
text
Medical Illness/Diagnosis
Item
Medical Illness/Diagnosis
text
Start Date
Item
Start Date (be as precise as possible)
date
End Date
Item
End Date (answer next question if Continuing)
boolean
Medication continuing?
Item
Medication continuing?
boolean
Item Group
RLS Pharmacotherapy history
Item
Has the patient taken any pharmacotherapy medication for treatment of RLS?
text
Code List
Has the patient taken any pharmacotherapy medication for treatment of RLS?
CL Item
No (1)
CL Item
Yes -> If "Yes", please record details below (2)
Item Group
Details RLS pharmacotherapy history
Drug Name
Item
Drug Name (Trade Name Preferred)
text
Start Date
Item
Start Date (be as precise as possible)
date
End Date
Item
End Date (or if continuing answer next question)
date
Medication continuing?
Item
Medication continuing?
boolean
Item
Did the patient respond to the treatment?
text
Code List
Did the patient respond to the treatment?
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown (3)
Item
Did the patient tolerate the treatment?
text
Code List
Did the patient tolerate the treatment?
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown (3)
Item Group
Screening Inclusion Criteria
IRLSSG diagnostic criteria
Item
1. Male or female subjects diagnosed with RLS using IRLSSG diagnostic criteria with a recent history of a minimum of 15 nights of RLS symptoms per month. Note: For a subject already receiving medication for RLS, the investigator should use their clinical judgement to decide whether that subject would suffer from a minimum of 15 nights with RLS symptoms if they were not taking any medication.
boolean
Clinically significant complaints
Item
2. Subjects must have reported clinically significant complaints of either sleep disruption or daytime consequences associated with the sleep disturbance.
boolean
Inclusion age
Item
3. Subjects >18 years and <80 years of age.
boolean
Contraception
Item
4. Women of child-bearing potential who are practicing a clinically accepted method of contraception such as oral contraception, surgical sterilization, IUD, diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception (i.e., Norplant). Please refer to document: CD-5.5, Informed Consent (Phase I-IV), section entitled ‘Recommendations For Use of Women Of Childbearing Potential in Clinical Research Studies for SmithKline Beecham’.
boolean
written informed consent
Item
5. The subject must have given written informed consent prior to any specific study procedure.
boolean
Information
Item
Usage Information seen
boolean
Item Group
Screening Exclusion Criteria
RLS symptoms
Item
1. Subjects suffering from RLS symptoms which require treatment during the daytime (daytime defined as 10:00 until 18:00)
boolean
Dissomnia or Parasomnia
Item
2. Subjects who suffer from a dissomnia or parasomnia other than RLS (e.g. narcolepsy, sleep terror disorder, sleepwalking disorder, apnea/hypopnea index >5 per hour during total sleep time and a total oxygen saturation of <80%).
text
Movement disorders
Item
3. Subjects suffering from movement disorders (e.g. Parkinson´s Disease, dyskinesias, and dystonias).
boolean
Symptoms which could affect assessments of efficacy
Item
4. Subjects who have medical conditions with symptoms which could affect assessments of efficacy (e.g. diabetes, peripheral neuropathy, rheumatoid arthritis, fibromyalgia syndrome, etc.).
boolean
change in dose of hormone replacement
Item
5. Subjects who have had withdrawal, introduction, or change in dose of hormone replacement therapy (HRT) and/or any drug known to substantially inhibit CYP1A2 (e.g., ciprofloxacin, fluvoxamine, cimetidine, HRT) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrollment.
boolean
intolerance to dopamine agonist
Item
6. Subjects who have exhibited intolerance to ropinirole or any other dopamine agonist.
boolean
substance abuse
Item
7. Subjects who meet DSM-IV criteria for substance abuse (alcohol or drugs) or substance dependence within six month prior to screening.
boolean
Pergnancy/lactating
Item
8. Woman who have a positive pregnancy test or who are lactating.
boolean
Subject unsuitable for study
Item
9. Subjects who have clinically significant or unstable medical conditions which in the opinion of the investigator would render the subject unsuitable for the study (e.g. severe cardiovascular disease, symptomatic orthostatic hypotension, hepatic or renal failure, etc.).
text
non-compliance with the visit schedule or other study procedures
Item
10. Subjects who, in the opinion of the investigator, would be non-compliant with the visit schedule or other study procedures.
boolean
participation in any clinical drug or device trial
Item
11. Participation in any clinical drug or device trial in the three month prior to the screening visit.
boolean
Information
Item
Usage Information
boolean
Item Group
Repeat electrocardiogram (12 Lead)
12 lead ECG
Item
Date of ECG.
date
Item
Were any clinically significant abnormalities detected?
text
Code List
Were any clinically significant abnormalities detected?
CL Item
No (1)
CL Item
Yes -> If yes, please record details in the Baseline Signs and Symptoms and/or SAE section at the back of this book and exclude the patient from the study. (2)
Repeat physical examination
Item
If any abnormality was present at screening please perform a physical examination. If there are any significant abnormal findings record details in the Baseline Signs and Symptoms and/or SAE section at the back of this book and exclude the patient from the study.
text
Repeat laboratory evaluation
Item
Date of sample
date
Item
Were any clinically significant abnormalities detected?
text
Code List
Were any clinically significant abnormalities detected?
CL Item
No (1)
CL Item
Yes -> If "yes", please record the findings and/or diagnosis in the Baseline Signs and Symptoms and/or SAE section at the back of this book and exclude the patient from the study. (2)
Patient activity postcard
Item
Please complete the patient activity postcard for Screening Repeat Tests located in the poastcard section of this CRF. Detach the postcard and mail promptly. Postage has been prepaid.
text